Patrys has today announced that its wholly-owned subsidiary Nucleus Therapeutics Pty Ltd has received a $3.35 million R&D Tax Incentive Refund for the 2021/22 financial year.
Patrys Chief Executive Officer and Managing Director, Dr. James Campbell, commented:
“For Patrys, this current rebate, in combination with our existing cash balance, has enabled the
Company to confidently continue advancing PAT-DX1 towards the clinic in the second half of 2023
despite challenging conditions in both the industry and capital markets.”